Gut-liver axis dysregulation and restoration in decompensated hepatitis B cirrhosis: rationale and research progress of fecal microbiota transplantation
- 1Department of Gastroenterology, Huaihai Hospital Affiliated to Xuzhou Medical University
- 2Department of Hepatology, Xuzhou Infectious Disease Hospital
Abstract
Decompensated hepatitis B virus (HBV) related cirrhosis is associated with high mortality and a wide range of complications. Current antiviral and symptomatic treatments fail to reverse core pathological alterations, including disruption of the gut microbial ecosystem. Gut-liver axis imbalance represents a central hub in disease progression. Gut dysbiosis compromises the intestinal mucosal barrier, leading to endotoxin translocation into the bloodstream, which in turn exacerbates hepatic inflammation and fibrosis, thereby establishing a vicious cycle. This review synthesizes the key mechanisms, clinical efficacy, administration routes, and safety profile of fecal microbiota transplantation (FMT) in this disease. It also identifies current technical bottlenecks and research gaps in FMT application and discusses future directions toward precision based and standardized clinical translation of this therapeutic approach.
Related
- Faecal microbiota transplantation for treatment of chronic urticaria with recurrent abdominal pain and food allergy
- Bletilla striata-derived extracellular vesicles armed probiotic by supramolecular assembly ameliorates colitis via macrophage modulation and microbiota restoration.
- Gut microbiota–mediated tryptophan metabolic dysregulation in the comorbidity of inflammatory bowel disease and autism spectrum disorder: mechanisms and research progress
- The Microbiota–Gut–Brain Axis in Obesity: Inflammation, Appetite Dysregulation, and Feeding Behavior
- Postelectroacupuncture Fecal Microbiota Transplantation (post‐EA FMT) Regulates Gastrointestinal Hormones in Functional Dyspepsia Rats Is Associated With Modulation of the Intestinal Microbiota‐Bile Acid Metabolic Pathway
BibTeX
@article{gao2026gutliver,
title = {{Gut-liver axis dysregulation and restoration in decompensated hepatitis B cirrhosis: rationale and research progress of fecal microbiota transplantation}},
author = {Shujuan Gao and Jie Zhuang and Hui Cheng and Kai Hu and Liwei Zhuang and Yong Pan},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1949414},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1949414/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gut-liver axis dysregulation and restoration in decompensated hepatitis B cirrhosis: rationale and research progress of fecal microbiota transplantation
AU - Shujuan Gao
AU - Jie Zhuang
AU - Hui Cheng
AU - Kai Hu
AU - Liwei Zhuang
AU - Yong Pan
PY - 2026
DA - 2026/10/14
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1949414
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1949414/full
AB - Decompensated hepatitis B virus (HBV) related cirrhosis is associated with high mortality and a wide range of complications. Current antiviral and symptomatic treatments fail to reverse core pathological alterations, including disruption of the gut microbial ecosystem. Gut-liver axis imbalance represents a central hub in disease progression. Gut dysbiosis compromises the intestinal mucosal barrier, leading to endotoxin translocation into the bloodstream, which in turn exacerbates hepatic inflammation and fibrosis, thereby establishing a vicious cycle. This review synthesizes the key mechanisms, clinical efficacy, administration routes, and safety profile of fecal microbiota transplantation (FMT) in this disease. It also identifies current technical bottlenecks and research gaps in FMT application and discusses future directions toward precision based and standardized clinical translation of this therapeutic approach.
SN - 1664-302X
ER -